Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada

• Published in: PLoS medicine 2010-04, Vol.7 (4), p.e1000258
• Main Authors: Skowronski, Danuta M, De Serres, Gaston, Crowcroft, Natasha S, Janjua, Naveed Z, Boulianne, Nicole, Hottes, Travis S, Rosella, Laura C, Dickinson, James A, Gilca, Rodica, Sethi, Pam, Ouhoummane, Najwa, Willison, Donald J, Rouleau, Isabelle, Petric, Martin, Fonseca, Kevin, Drews, Steven J, Rebbapragada, Anuradha, Charest, Hugues, Hamelin, Marie-Eve, Boivin, Guy, Gardy, Jennifer L, Li, Yan, Kwindt, Trijntje L, Patrick, David M, Brunham, Robert C
• Format: Article
• Language: English
• Subjects: Canada - epidemiology; Demographic aspects; Disease Outbreaks; Forecasts and trends; Humans; Illnesses; Infectious Diseases; Infectious Diseases/Epidemiology and Control of Infectious Diseases; Infectious Diseases/Respiratory Infections; Infectious Diseases/Viral Infections; Influenza A Virus, H1N1 Subtype - pathogenicity; Influenza Vaccines - adverse effects; Influenza, Human - epidemiology; Influenza, Human - virology; Medical research; Methods; Observation; Observational studies; Pandemics; Public health; Public Health and Epidemiology; Public Health and Epidemiology/Immunization; Public Health and Epidemiology/Infectious Diseases; Public Health and Epidemiology/Preventive Medicine; Respiratory Medicine/Respiratory Infections; Studies; Swine flu; Swine influenza; Vaccination; Vaccines
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1000258

In late spring 2009, concern was raised in Canada that prior vaccination with the 2008-09 trivalent inactivated influenza vaccine (TIV) was associated with increased risk of pandemic influenza A (H1N1) (pH1N1) illness. Several epidemiologic investigations were conducted through the summer to assess this putative association. (1) test-negative case-control design based on Canada's sentinel vaccine effectiveness monitoring system in British Columbia, Alberta, Ontario, and Quebec; (2) conventional case-control design using population controls in Quebec; (3) test-negative case-control design in Ontario; and (4) prospective household transmission (cohort) study in Quebec. Logistic regression was used to estimate odds ratios for TIV effect on community- or hospital-based laboratory-confirmed seasonal or pH1N1 influenza cases compared to controls with restriction, stratification, and adjustment for covariates including combinations of age, sex, comorbidity, timeliness of medical visit, prior physician visits, and/or health care worker (HCW) status. For the prospective study risk ratios were computed. Based on the sentinel study of 672 cases and 857 controls, 2008-09 TIV was associated with statistically significant protection against seasonal influenza (odds ratio 0.44, 95% CI 0.33-0.59). In contrast, estimates from the sentinel and three other observational studies, involving a total of 1,226 laboratory-confirmed pH1N1 cases and 1,505 controls, indicated that prior receipt of 2008-09 TIV was associated with increased risk of medically attended pH1N1 illness during the spring-summer 2009, with estimated risk or odds ratios ranging from 1.4 to 2.5. Risk of pH1N1 hospitalization was not further increased among vaccinated people when comparing hospitalized to community cases. Prior receipt of 2008-09 TIV was associated with increased risk of medically attended pH1N1 illness during the spring-summer 2009 in Canada. The occurrence of bias (selection, information) or confounding cannot be ruled out. Further experimental and epidemiological assessment is warranted. Possible biological mechanisms and immunoepidemiologic implications are considered.